| Management of post‐transplant lymphoproliferative disorders CB DeStefano, SH Desai, AG Shenoy, JP Catlett British journal of haematology 182 (3), 330-343, 2018 | 77 | 2018 |
| Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors C Pleyer, C Sun, S Desai, IE Ahn, X Tian, P Nierman, S Soto, J Superata, ... Leukemia & lymphoma 61 (10), 2375-2382, 2020 | 23 | 2020 |
| Artificial intelligence in inflammatory bowel disease endoscopy: current landscape and the road ahead S Sundaram, T Choden, MC Mattar, S Desai, M Desai Therapeutic Advances in Gastrointestinal Endoscopy 14, 26317745211017809, 2021 | 15 | 2021 |
| Role of anti-EGFR targeted therapies in stage III locally advanced non-small cell lung cancer: give or not to give? S Desai, C Kim, I Veytsman Current oncology reports 21, 1-7, 2019 | 14 | 2019 |
| Checkpoint inhibitor‐based salvage regimens prior to autologous stem cell transplant improve event‐free survival in relapsed/refractory classic Hodgkin lymphoma SH Desai, MA Spinner, K David, V Bachanova, G Goyal, B Kahl, K Dorritie, ... American journal of hematology 98 (3), 464-471, 2023 | 7 | 2023 |
| Future directions in Hodgkin lymphoma: checkpoint inhibitors and beyond S Desai, SM Ansell Leukemia & Lymphoma 62 (8), 1795-1804, 2021 | 6 | 2021 |
| Diffuse myocardial fibrosis is greatly elevated in males with heart failure with reduced ejection fraction, but not heart failure with preserved ejection fraction S Desai, P Haines, P Zamani, P Konda, P Shiva-Kumar, S Peddireddy, ... Journal of the American College of Cardiology 63 (12S), A967-A967, 2014 | 6 | 2014 |
| Novel salvage regimens lead to better response and survival in relapsed refractory classic Hodgkin lymphoma after autologous stem cell transplant SH Desai, MA Spinner, KA David, V Bachanova, G Goyal, J Azzi, ... Blood 138, 878, 2021 | 5 | 2021 |
| Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular … SH Desai, B LaPlant, WR Macon, RL King, Y Wang, DJ Inwards, I Micallef, ... Blood cancer journal 11 (9), 160, 2021 | 5 | 2021 |
| Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world … CB Wagner, K Boucher, A Nedved, IN Micallef, S Desai, H Hatic, G Goyal, ... Haematologica 108 (11), 3025, 2023 | 4 | 2023 |
| Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the … CB Wagner, DA Ermann, K Boucher, AN Nedved, IN Micallef, SH Desai, ... Blood 140 (Supplement 1), 9390-9392, 2022 | 4 | 2022 |
| Lymphoma survivors have an increased long-term risk of chronic kidney disease SH Desai, G Al-Shbool, S Desale, J Veis, V Malkovska Leukemia & Lymphoma 61 (12), 2923-2930, 2020 | 4 | 2020 |
| PD-1 Blockade before Autologous Stem Cell Transplantation Improves Outcomes in Relapsed/Refractory Classic Hodgkin Lymphoma: Results from a Multicenter Cohort SH Desai, RW Merryman, H Shah, LD Pederson, SM Geyer, N Ganesan, ... Blood 142, 182, 2023 | 3 | 2023 |
| Phase 1 trial of Ruxolitinib combined with Nivolumab in patients relapsed/refractory Hodgkin lymphoma after failure of check‐point inhibitor (CPI) V Bachanova, J Zak, Q Cao, J Maakaron, B Grzywacz, C Fletcher, ... Hematological oncology 41, 582-582, 2023 | 3 | 2023 |
| Outcomes of classic Hodgkin lymphoma, relapsed within one year of diagnosis, in the era of novel agents. S Desai, MA Spinner, KA David, V Bachanova, G Goyal, R Saba, ... Journal of Clinical Oncology 40 (16_suppl), 7515-7515, 2022 | 3 | 2022 |
| Single-Center Analysis of Characteristics and Outcomes of De Novo, Concurrent, and Transformed Diffuse Large B-Cell Lymphoma S Desai, M Chaturvedi, R Hameed, V Baez-Sosa, AG Shenoy The Oncologist 26 (9), e1660-e1663, 2021 | 3 | 2021 |
| Prevalence of chronic kidney disease (CKD) in lymphoma survivors G Al-Shbool, S Desale, J Veis, V Malkovska, S Desai Blood 134, 2912, 2019 | 3 | 2019 |
| Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era SH Desai, MA Spinner, AM Evens, A Sykorova, V Bachanova, G Goyal, ... Blood Advances 7 (23), 7295-7303, 2023 | 2 | 2023 |
| Efficacy of Brentuximab Vedotin Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma with and … AS Falade, RA Redd, H Shah, K Baron, S Iyengar, SH Desai, SM Ansell, ... Blood 142, 3062, 2023 | 2 | 2023 |
| PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts SH Desai, L Pederson, B LaPlant, R Mwangi, M Maurer, JR Young, ... Blood cancer journal 12 (5), 78, 2022 | 2 | 2022 |
